Elanco Animal Health Incorporated $ELAN Shares Purchased by LPL Financial LLC

Key Points

• LPL Financial LLC increased its stake in Elanco Animal Health, acquiring an additional 38,412 shares, bringing its total holdings to 199,595 shares, valued at approximately $2.1 million.
• Elanco Animal Health posted a quarterly EPS of $0.26, exceeding analysts' expectations, with revenue of $1.24 billion, marking a 4.8% increase year-over-year.
• Institutional investors hold 97.48% of Elanco Animal Health, with various firms adjusting their positions significantly during the fourth quarter and first quarter of 2025.

LPL Financial LLC raised its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 23.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 199,595 shares of the company's stock after purchasing an additional 38,412 shares during the quarter. LPL Financial LLC's holdings in Elanco Animal Health were worth $2,096,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Graypoint LLC grew its stake in shares of Elanco Animal Health by 4.9% in the 1st quarter. Graypoint LLC now owns 26,845 shares of the company's stock valued at $282,000 after purchasing an additional 1,256 shares during the last quarter. Resonant Capital Advisors LLC grew its stake in shares of Elanco Animal Health by 5.7% in the 1st quarter. Resonant Capital Advisors LLC now owns 29,414 shares of the company's stock valued at $309,000 after purchasing an additional 1,576 shares during the last quarter. Freedom Investment Management Inc. grew its stake in shares of Elanco Animal Health by 9.1% in the 4th quarter. Freedom Investment Management Inc. now owns 20,746 shares of the company's stock valued at $251,000 after purchasing an additional 1,725 shares during the last quarter. Versant Capital Management Inc grew its stake in shares of Elanco Animal Health by 65.9% in the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock valued at $46,000 after purchasing an additional 1,740 shares during the last quarter. Finally, Mitchell & Pahl Private Wealth LLC grew its stake in shares of Elanco Animal Health by 4.0% in the 1st quarter. Mitchell & Pahl Private Wealth LLC now owns 45,489 shares of the company's stock valued at $478,000 after purchasing an additional 1,761 shares during the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Leerink Partners upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 target price on the stock in a research note on Thursday, July 17th. UBS Group lifted their price target on Elanco Animal Health from $18.00 to $19.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Leerink Partnrs upgraded Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 17th. Wall Street Zen upgraded Elanco Animal Health from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. Finally, Stifel Nicolaus lifted their price target on Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research note on Wednesday, July 2nd. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $17.33.

Elanco Animal Health Price Performance

Shares of Elanco Animal Health stock traded up $0.4030 during trading on Friday, reaching $17.8930. The company's stock had a trading volume of 6,722,648 shares, compared to its average volume of 6,561,933. The business has a 50 day moving average price of $15.08 and a 200-day moving average price of $12.47. The company has a market capitalization of $8.89 billion, a P/E ratio of 20.81, a price-to-earnings-growth ratio of 3.25 and a beta of 1.66. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $18.08. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.06. The firm had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.Elanco Animal Health's revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.